Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | GRK2 | P25098 | 11/20 | 0.40 |
| ▸ | GRK5 | P34947 | 2/20 | 0.36 |
| ▸ | GRK3 | P35626 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.35 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA1 | P00915 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | CA9 | Q16790 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | ACHE | P22303 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1180296 | 1.00 | NPSR1 (0.43) | NPSR1GRK2GRK5GRK3HTT | |
| SCHEMBL19769023 | 0.81 | GRK2 (0.32) | NPSR1GRK2MAPTSMN1; SMN2LMNA | |
| SCHEMBL20621290 | 0.81 | GRK2 (0.32) | NPSR1GRK2MAPTSMN1; SMN2LMNA | |
| SCHEMBL22096814 | 0.81 | HTT (0.40) | NPSR1GRK2HTTMAPTSMN1; SMN2 | |
| SCHEMBL5282764 | 0.78 | NPSR1 (0.44) | NPSR1GRK2GRK5GRK3HTT | |
| SCHEMBL19779864 | 0.76 | GRK2 (0.33) | GRK2HTTMAPT | |
| SCHEMBL1920495 | 0.76 | HTT (0.33) | NPSR1HTTMAPTCDK5CDK5R1 | |
| SCHEMBL1920497 | 0.76 | HTT (0.33) | NPSR1HTTMAPTCDK5CDK5R1 | |
| SCHEMBL533867 | 0.73 | SMN1; SMN2 (0.55) | NPSR1HTTSMN1; SMN2CA12CA1 | |
| SCHEMBL2010954 | 0.73 | SMN1; SMN2 (0.55) | NPSR1HTTSMN1; SMN2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 65 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055094-A1 | FXR (NR1H4) MODULATING COMPOUNDS | GILEAD SCIENCES INC (US) | 2026-02-26 | — | — | US | disclosed |
| US-12358903-B2 | FXR (NR1H4) modulating compounds | GILEAD SCIENCES, INC. (US) | 2025-07-15 | — | — | US | disclosed |
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-3704112-B1 | ALKENE SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-3704114-B1 | SPIROCYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-11-23 | — | — | EP | disclosed |
| US-20220242858-A1 | FXR (NR1H4) MODULATING COMPOUNDS | PHENEX PHARMACEUTICALS AG (DE) | 2022-08-04 | — | — | US | disclosed |
| US-11339147-B2 | Lactam compound as FXR receptor agonist | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2022-05-24 | — | — | US | disclosed |
| EP-3730487-B1 | AZETIDINE DERIVATIVES AS FXR (NR1H4) MODULATORS | GILEAD SCIENCES INC (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3730487-B1 | AZETIDINE DERIVATIVES AS FXR (NR1H4) MODULATORS | GILEAD SCIENCES INC (US) | 2022-04-27 | — | — | EP | disclosed |
| WO-2008051942-A2 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008051942-A2 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-05-02 | — | — | WO | disclosed |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-04-24 | — | — | US | disclosed |
| US-7037921-B2 | Useful for inhibiting resistant neoplasms where the resistance is conferred in part or in total by multidrug resistance protein MRP1 | ELI LILLY AND COMPANY (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1392702-B1 | COMPOUNDS AND METHODS FOR INHIBITING MRP1 | LILLY CO ELI (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20040097507-A1 | Compounds and methods for inhibiting mrp1 | BONJOUKLIAN ROSANNE (US) | 2004-05-20 | — | — | US | disclosed |
| EP-1392702-A1 | COMPOUNDS AND METHODS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2004-03-03 | — | — | EP | disclosed |
| WO-2002081482-A1 | COMPOUNDS AND METHODS FOR INHIBITING MRP1 | ELI LILLY AND COMPANY (US) | 2002-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12358903-B2 | FXR (NR1H4) modulating compounds | NR1H4, NR1H2, NR1H3 | NPSR1 736/4885GRK2 86/4885GRK5 67/4885 |
| US-20040097507-A1 | Compounds and methods for inhibiting mrp1 | ABCC1, ABCB1, ABCB11 | NPSR1 3966/4885GRK2 4144/4885GRK5 3485/4885 |
| US-11339147-B2 | Lactam compound as FXR receptor agonist | NR1H4, GPBAR1, SLC10A1 | NPSR1 373/4885GRK2 185/4885GRK5 111/4885 |
| US-20220242858-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NPSR1 736/4885GRK2 86/4885GRK5 67/4885 |
| US-20260055094-A1 | FXR (NR1H4) MODULATING COMPOUNDS | NR1H4, NR1H2, NR1H3 | NPSR1 477/4885GRK2 67/4885GRK5 78/4885 |
| US-20080096921-A1 | FARNESOID X RECEPTOR AGONISTS | NR1H4, NR1H3, NR1H2 | NPSR1 266/4885GRK2 174/4885GRK5 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.